Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

被引：1
|
作者：
Rodon, J. [1 ]
Peltola, K. [2 ]
Azaro, A. [1 ]
Alvarez, E. Castanon [3 ]
Garratt, C. [4 ]
Leskinen, H. [5 ]
Bjorklund, H. [6 ]
Ruck, A. [4 ]
Massard, C. [3 ]
Bono, P. [2 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain
[2] Univ Helsinki, Cent Hosp, Comprehens Canc Ctr, Helsinki, Finland
[3] Inst Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[4] Orion Pharma, Oncol & Crit Care, Nottingham, England
[5] Orion Pharma, Drug Safety, Helsinki, Finland
[6] Orion Pharma, Drug Metab, Turku, Finland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of BIBF 1120, an orally active triple angiolkinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies.
    Lee, CP
    Attard, G
    Poupard, L
    Nathan, PD
    de Bono, JS
    Temple, GMR
    Stefanic, MF
    Padhani, AR
    Judson, IR
    Rustin, GJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 205S - 205S
  • [22] FIRST-IN-MAN STUDY OF E-3810, A NOVEL VEGFR AND FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Soria, J. C.
    Dienstmann, R.
    de Braud, F.
    Cereda, R.
    Bahleda, R.
    Hollebecque, A.
    Tabernero, J.
    Delmonte, A.
    Dromain, C.
    Lassau, N.
    Farace, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2012, 23 : 16 - 17
  • [23] First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors
    Soria, J. C.
    De Braud, F.
    Cereda, R.
    Bahleda, R.
    Delmonte, A.
    Angevin, E.
    Varga, A.
    Noberasco, C.
    Dall'O', E.
    Lassau, N.
    Dromain, C.
    Bellomi, M.
    Farace, F.
    Bertolini, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2011, 22 : 40 - 40
  • [24] Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Nokihara, Hiroshi
    Fujiwara, Yutaka
    Hirata, Taizo
    Yamamoto, Nobuyuki
    Boku, Narikazu
    Shin, Eisei
    Tamura, Tomohide
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3417S - 3418S
  • [25] PHASE I STUDY OF CEDIRANIB, A VEGFR SIGNALING INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Takahashi, T.
    Yamamoto, N.
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Yamada, Y.
    Yamada, K.
    Shin, E.
    Puchalski, T. A.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 159 - 159
  • [26] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
    Bahleda, R.
    Meric-Bernstam, F.
    Goyal, L.
    Tran, B.
    He, Y.
    Yamamiya, I
    Benhadji, K. A.
    Matos, I
    Arkenau, H-T
    ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
  • [27] A phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours
    Shaw, H. M.
    Molife, L. R.
    Spicer, J.
    Karavasilis, V.
    Marriott, C.
    Ong, T. J.
    Tate, L.
    Brendel, E.
    Christensen, O.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael
    Yung-Jue Bang
    Young Suk Park
    Yoon-Koo Kang
    Tae Min Kim
    Oday Hamid
    Donald Thornton
    Sonya C. Tate
    Eyas Raddad
    Jeanne Tie
    Targeted Oncology, 2017, 12 : 463 - 474
  • [29] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael, Michael
    Bang, Yung-Jue
    Park, Young Suk
    Kang, Yoon-Koo
    Kim, Tae Min
    Hamid, Oday
    Thornton, Donald
    Tate, Sonya C.
    Raddad, Eyas
    Tie, Jeanne
    TARGETED ONCOLOGY, 2017, 12 (04) : 463 - 474
  • [30] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
    Xu, Jianming
    Cui, Jiuwei
    Jiang, Haiping
    Zeng, Yan
    Cong, Xiuyu
    CANCER MEDICINE, 2023, 12 (07): : 7762 - 7771
12345